Eli Lilly antibody treatment trial put on pause due to safety concerns

Published



Pharmaceutical giant Eli Lilly has paused late-stage clinical trials for its coronavirus antibody treatment due to safety issues.

“Safety is of the utmost importance to Lilly,” Eli Lilly spokesperson Molly McCully said in a written statement to the Washington Examiner. “We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.